

27 May 2026

Intra-vitreous injections or implants

I am analysing the usage of intra-vitreous injections or implants by the NHS. I would greatly appreciate if you could answer the following questions.

Please note for both questions, if a patient has received multiple injection/implants in the time period specified of January to April 2026, please count the total number of injections/implants that the Trust has administered. I.e. if a patient has received two injections/implants please count that as two.

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2026:

- **Aflibercept**

Total administrations: 2,103

- **Aflibercept – Biosimilar**

Included within the Aflibercept total above.

- **Bevacizumab**

Total administrations: <5

- **Brolucizumab**

Not administered during the timeframe specified.

- **Dexamethasone**

Total administrations: 7

- **Faricimab**

Total administrations: 3,296

- **Fluocinolone acetonide**

Total administrations: 28

27 May 2026

- **Ranibizumab - including all Biosimilars**

Not administered during the timeframe specified.

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2026:

- **Aflibercept – Eylea**
- **Aflibercept - Biosimilar**
- **Bevacizumab**
- **Dexamethasone**
- **Faricimab**
- **Fluocinolone acetonide**
- **Ranibizumab - including all Biosimilars**

A total of 5,346 administrations were recorded within the timeframe specified. Of these, 1,075 administrations have an associated diagnosis recorded within the system problem list.

It is not possible to provide diagnosis information for the remaining 4,271 administrations, as this would require a manual review of individual patient records. Therefore, under Section 12(1) of the Freedom of Information Act 2000, Belfast Trust unable to provide this information as the cost of compliance exceeds the prescribed limit (equivalent to 18 hours of staff time).

The available data for the 1,075 administrations with recorded diagnoses is provided below. *Please note:* These figures include patients who received bilateral injections, which are counted as two administrations.

Treatment	Eye Condition			
	Wet Age-Related Macular Degeneration	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)	Non-infectious Uveitis (NIU)
Aflibercept - Eylea	77	230	123	n/a
Aflibercept – Biosimilar	n/a			n/a
Bevacizumab	n/a			n/a
Dexamethasone	<5	<5	<5	
Faricimab	118	311	181	n/a
Fluocinolone acetonide	11	11	6	
Ranibizumab - including all Biosimilars	n/a			n/a

27 May 2026

Some figures have been withheld and replaced with less than five (<5). This is because disclosure of small numbers may risk identifying individuals. The information is therefore exempt under Section 40(2) of the Freedom of Information Act 2000 - Personal Information relating to a third party. Its release would contravene the data protection principles set out in the UK GDPR.